Many biotechnology companies are looking hard at their patent portfolios to raise extra
revenues. Orrick, Herrington & Sutcliffe's Craig Kaufman and Anne-Marie Dinius
reveal how biotech companies can use the law to enhance their ability to enforce their
Unlock this article.
The content you are trying to view is exclusive to our subscribers.